Trading Symbol
JUBLINGREA (NSE)
Key Financial Figures
Q2 FY27 Performance (YoY Comparison):
- Total Revenue: ₹1,394 crore (up 24% from ₹1,121 crore in Q2 FY26)
- Total EBITDA: ₹221 crore (up 51% from ₹146 crore in Q2 FY26)
- EBITDA Margin: 16% (vs 13% in Q2 FY26)
- PAT after Exceptional Items: ₹111 crore (up 61% from ₹69 crore in Q2 FY26)
- PAT Margin: 8% (vs 6% in Q2 FY26)
- Basic and Diluted EPS: ₹7.1 (up 61% from ₹4.4 in Q2 FY26)
H1 FY27 Performance (YoY Comparison):
- Total Revenue: ₹2,695 crore (up 25% from ₹2,159 crore in H1 FY26)
- Total EBITDA: ₹431 crore (up 44% from ₹300 crore in H1 FY26)
- PAT after Exceptional Items: ₹217 crore (up 50% from ₹145 crore in H1 FY26)
- Basic and Diluted EPS: ₹13.8 (up 50% from ₹9.2 in H1 FY26)
Segment-wise Performance Q2 FY27
Specialty Chemicals Segment:
- Revenue: ₹560 crore (up 16% YoY, 5% QoQ)
- EBITDA: ₹140 crore (up 12% YoY, 1% QoQ)
- EBITDA Margin: 25% (vs 26% in Q2 FY26)
- Contribution to Overall EBITDA: 58% (before corporate expense adjustment)
Nutrition & Health Solutions Segment:
- Revenue: ₹270 crore (up 50% YoY, 11% QoQ)
- EBITDA: ₹39 crore (up 87% YoY, 9% QoQ)
- EBITDA Margin: 14% (vs 12% in Q2 FY26)
- Contribution to Overall EBITDA: 17% (before corporate expense adjustment)
Chemical Intermediates Segment:
- Revenue: ₹563 crore (up 24% YoY, 8% QoQ)
- EBITDA: ₹64 crore (up 226% YoY, 13% QoQ)
- EBITDA Margin: 11% (vs 4% in Q2 FY26)
- Contribution to Overall EBITDA: 26% (before corporate expense adjustment)
Strategic Update: ZettaOne Acquisition
- Signed agreement to acquire 40% stake in ZettaOne Technologies Limited
- Investment amount: ₹189.2 crore
- Transaction progressing well, shareholders' agreement to be concluded soon
- ZettaOne operates in Electronics Development and Manufacturing Services (EDMS) space
- Expected to provide access to broader electronics and semiconductor ecosystem
- Business expected to grow 60-70% in current year
- New manufacturing facility being established near Bengaluru
Operational Highlights
Market Conditions:
- Geopolitical uncertainties continued, volumes remained stable
- Firmer crude prices supported improved realizations
- Higher input and utility costs partially offset pricing benefits
- Pharmaceutical sector grew with steady volumes
- Agrochemicals segment under pressure with China overcapacity
- Personal Care showing strong volume growth
- Nutrition segment maintained steady volumes despite softening B3 pricing
- Semiconductors/Electronics showing strong growth in new-molecule pipeline
Business Segment Updates:
Specialty Chemicals:
- Pyridine & Picolines: Volumes stable, prices soft
- Fine Chemicals: Broad-based growth across products, improved pricing
- CDMO: Strong momentum across Agro, Pharma, and Semiconductors with 25+ confirmed molecules in pipeline
- Upcoming R&D and clean-room facility in Greater Noida
Nutrition & Health Solutions:
- Human Nutrition: Strong Vitamin B3 volume growth in Food and Cosmetics applications
- Animal Nutrition: Significant volume improvement, pricing marginally soft
- Remidex integration driving stronger customer engagement
Chemical Intermediates:
- Acetic Anhydride: Sequential volume growth, market share gains in Europe
- Ethyl Acetate: Steady sequential volume growth, significant pricing improvement
- Competitor closure in Europe expected to boost pricing and demand
Future Outlook
- Growth expected across all three business segments in FY27
- Particularly strong growth expected in Acetyls supported by plant closures in Europe
- New Multi-Purpose Plant on track for commissioning by year-end
- Pinnacle strategy delivering desired outcomes
- Confident of sustaining growth momentum
Additional Information
- Earnings call scheduled for October 27, 2026, at 5:00 PM IST
- Documents available on company website: www.jubilantingrevia.com
- Company has over 45 years of legacy in chemicals industry
- Operates 50+ plants across 6 manufacturing facilities in India
- Workforce of over 2,300 employees
- Three R&D centres with 150 scientists